Navigation Links
Allos Therapeutics to Present at the 2007 JMP Securities Healthcare Focus Conference
Date:11/7/2007

WESTMINSTER, Colo., Nov. 7 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that the Company will participate in the 2007 JMP Securities Healthcare Focus Conference in Boston.

The Company's presentation will take place at 12 p.m. (Eastern) on Tuesday, November 13, 2007. There will be a live webcast of the presentation, which will be accessible through a link posted on the Allos website home page and investor relations section. The webcast will be available for replay on Allos' website through November 27, 2007.

About Allos Therapeutics, Inc.

Allos Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is being conducted under an agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent, for which the Company expects to initiate a Phase 1 trial in patients with advanced solid tumors in the fourth quarter of 2007. For additional information, please visit the Company's website at http://www.allos.com.

Safe
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Regulus Therapeutics Inc . ... the discovery and development of innovative medicines targeting microRNAs, ... highlights for the quarter ended June 30, 2014 on ... close. Regulus will host a conference ... 5:00 pm Eastern Daylight Time to discuss its second ...
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... and NYSE: SNY) today announced that the Companies intend ... rare pediatric disease priority review voucher in connection with ... priority review voucher entitles the holder to designate a ... 6-month review from the filing date instead of the ...
(Date:7/30/2014)... 30, 2014 W. R. Grace ... of the REVELERIS® Prep purification system , ... chromatographers, and other researchers to perform both flash ... unit. , With the REVELERIS® Prep purification system, ... chromatography modes with a simple touch of the ...
(Date:7/30/2014)... July 30, 2014  Decision Resources Group finds ... directors in the United States ... market penetration will be the level of savings ... the expected lower cost to patients. Payers plan ... meet their pricing expectations in order to encourage ...
Breaking Biology Technology:Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Grace Launches New REVELERIS® Prep Purification System 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3
... Senomyx, Inc.,(Nasdaq: SNMX ) will release its ... before the opening of the U.S. financial,markets. The Company ... Internet,broadcast that will provide a business update and a ... at 11:00 a.m. Eastern Time (8:00 a.m.,Pacific Time)., ...
... Oct. 20 GeoVax Labs, Inc. (OTC,Bulletin Board: ... for diseases caused by HIV-1 (Human Immunodeficiency Virus),and ... both DNA and,MVA components of its AIDS vaccine ... use in the upcoming Phase 2a human clinical ...
... with Industry to Educate,Promote PRV Program-, WASHINGTON, ... today announced its support of the US Food ... Industry on Priority,Review Vouchers. The Priority Review Voucher ... the development of drugs and vaccines for,neglected tropical ...
Cached Biology Technology:SENOMYX, INC. THIRD QUARTER 2008 EARNINGS CONFERENCE CALL SCHEDULED FOR NOVEMBER 6, 2008 2GeoVax's DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial 2GeoVax's DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial 3FDA Issues Draft Guidance on Priority Review Vouchers 2
(Date:7/30/2014)... University is paving the way for a breakthrough ... military troops exposed to poisonous chemicalsparticularly those in ... in the current issue of the journal ... which are compounds commonly used in pesticides and ... NYU School of Engineering Associate Professor of Chemical ...
(Date:7/30/2014)... uses reversible epigenetic processes to regulate its genes, and ... a picture of the genome regulation taking place in ... Genome Biology and illustrates how the truffle ... genes,. The authors say this may shed light on ... Black truffles (Tuber melanosporum), also known as Prigord truffles, ...
(Date:7/30/2014)... the Red Queen in Lewis Carroll,s Through the ... and National University of Singapore improved a 35-year-old ... over decades to millions of years. , The ... competition, incorporates the "Red Queen Effect," an evolutionary ... 1970s, which suggests that organisms must constantly increase ...
Breaking Biology News(10 mins):Engineering a protein to prevent brain damage from toxic agents 2How black truffles deal with the jumpers in their genome 2Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3
... October 23, 2013 A promising technique for treating ... may lead to new treatments to prevent blindness, according to ... Jolla, California. The studies involved controlling the actions ... to be "junk" but are now known to fine-tune gene ...
... have found out which molecular mechanisms decide about the ... for the import of proteins into specific cell components, ... receptor remains active or is broken down after the ... regulation of the protein import into peroxisomes has been ...
... simply cannot do without lasers. We use them to print ... car components, survey roads, monitor our bloodstream, and even remove ... for Applied Solid State Physics IAF in Freiburg have developed ... a particular type of infrared laser forms the ...
Cached Biology News:New eye treatment effective in laboratory tests 2New eye treatment effective in laboratory tests 3New eye treatment effective in laboratory tests 4The yin and yang in the life of proteins 2Lasers offer an automated way to test drinking water 2Lasers offer an automated way to test drinking water 3
Mouse monoclonal antibody raised against a full length recombinant GPT. NCBI Entrez Gene ID = GPT...
Mouse monoclonal antibody raised against a partial recombinant TPR. NCBI Entrez Gene ID = TPR...
... Each kit contains sufficient materials for 1,464 array sample ... Membrane: 4 each , Blocker BSA in PBS (10X): ... BupH Phosphate Buffered Saline: 8 packs , 10% Tween-20: ... Luminol Enhancer: 2 x 25 ml , SuperSignal West ...
... 100-120 V, is used for biolistic particle ... device employs an adjustable helium pulse to ... microcarriers from the inner wall of a ... This system has a 2 square-centimeter target ...
Biology Products: